Filing Details

Accession Number:
0001181431-11-019470
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2011-03-22 16:25:57
Reporting Period:
2010-12-08
Filing Date:
2011-03-22
Accepted Time:
2011-03-22 16:25:57
Original Submission Date:
2010-12-09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1325879 Aveo Pharmaceuticals Inc AVEO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1486373 G. Douglas Cole C/O Aveo Pharmaceuticals, Inc.
75 Sidney Street
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-12-08 25,838 $14.93 718,505 No 4 S Indirect by Applied Genomic Technology Capital Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect by Applied Genomic Technology Capital Fund, L.P.
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Applied Genomic Technology Capital Fund, L.P. on November 9, 2010.
  2. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.72 to $15.02, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
  3. The number of shares were incorrectly reported on the reporting person's Form 4 filed on December 9, 2010, and on subsequent Forms 4 filed by the reporting person.
  4. Held by Applied Genomic Technology Capital Fund, L.P.; NewcoGen Group, Inc. ("NewcoGen") is the general partner of AGTC Partners, L.P., which is the general partner of Applied Genomic Technology Capital Fund, L.P. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc.("Flagship"). Noubar B. Afeyan Ph.D. and Edwin M. Kania, Jr. are the directors of Flagship Inc. and they may be deemed to have beneficial ownership with respect to all shares held by Applied Genomic Technology Capital Fund, L.P. The reporting person disclaims beneficial ownership over shares held by Applied Genomic Technology Capital Fund, L.P.